On November 11, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, will participate in a panel discussion titled, "Show Me the Money: Preparing Your Company for Funding," at the annual NYC-based Life Sciences Summit, taking place virtually November 17-18, 2020 (Press release, Genprex, NOV 11, 2020, View Source [SID1234570566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Life Sciences Summit

Panel: Show Me the Money: Preparing Your Company for Funding

Date: Tuesday, November 17

Time: 10-10:45 a.m. ET

Registration Link: https://bit.ly/3kXMpHZ

During this discussion, the panel experts will provide an insider’s guide into the essential building blocks needed for emerging companies to reach their goals. The panelists will share their knowledge on topics such as intellectual property strategy, due diligence, valuation, and building relationships with investors and partners.

Organized by the Center for Biotechnology, the Life Sciences Summit is an early-stage investor and business development conference for emerging companies and academic innovators. The objective of the meeting is to connect emerging companies with early-stage investors, business development professionals, and medical research foundations with the goal of advancing new innovations through clinical development.